{
    "clinical_study": {
        "@rank": "102509", 
        "acronym": "IMAGO", 
        "arm_group": [
            {
                "arm_group_label": "LUM001", 
                "arm_group_type": "Experimental", 
                "description": "LUM001 administered orally once each day"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo administered orally once each day"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is a randomized, double-blind, placebo-controlled study to evaluate the safety and\n      tolerability of LUM001.  Efficacy will be assessed by evaluating the effect of LUM001 versus\n      placebo on the biochemical markers and pruritus associated with Alagille Syndrome."
        }, 
        "brief_title": "Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Alagille Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Liver Diseases", 
                "Alagille Syndrome", 
                "Cholestasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Diagnosis of Alagille Syndrome\n\n          2. Evidence of cholestasis\n\n          3. Moderate to severe pruritus\n\n          4. Ability to understand and willingness to sign informed consent/assent prior to\n             initiation of any study procedures\n\n        Exclusion Criteria:\n\n          1. Surgical disruption of the enterohepatic circulation\n\n          2. Liver transplant\n\n          3. History or presence of other concomitant liver disease\n\n          4. Females who are pregnant or lactating\n\n          5. Known HIV infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "12 Months"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01903460", 
            "org_study_id": "LUM001-302", 
            "secondary_id": "2012-005346-38"
        }, 
        "intervention": [
            {
                "arm_group_label": "LUM001", 
                "intervention_name": "LUM001", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 3, 2014", 
        "link": {
            "url": "http://www.lumenapharma.com"
        }, 
        "location": [
            {
                "contact": {
                    "email": "carla.lloyd@bch.nhs.uk", 
                    "last_name": "Carla Lloyd"
                }, 
                "contact_backup": {
                    "email": "Gemma.slinn@bch.nhs.uk", 
                    "last_name": "Gemma Slinn"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom", 
                        "state": "West Midlands", 
                        "zip": "B4 6NH"
                    }, 
                    "name": "Birmingham Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Deirdre Kelly, FRCPI, FRCP,FRCPCH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sarah.ashton@cmft.nhs.uk", 
                    "last_name": "Sarah Ashton"
                }, 
                "contact_backup": {
                    "email": "nicola.balatoni@leedsth.nhs.uk", 
                    "last_name": "Nicola Balatoni"
                }, 
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom", 
                        "state": "West Yorkshire", 
                        "zip": "LS9 7TF"
                    }, 
                    "name": "Leeds Teaching Hospitals"
                }, 
                "investigator": {
                    "last_name": "Patricia McClean, MD,FRCP,FRCPCH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pkarthikeyan@nhs.net", 
                    "last_name": "Palaniswamy Karthikeyan"
                }, 
                "contact_backup": {
                    "email": "harpreet.grewal@kcl.ac.uk", 
                    "last_name": "Harpreet Grewal"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE5 9RS"
                    }, 
                    "name": "Kings College Hospital"
                }, 
                "investigator": {
                    "last_name": "Alastair Baker, MBChB,FFARCS,MRCP,FRCPCH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Paediatric Patients With Alagille Syndrome", 
        "other_outcome": {
            "description": "Evaluation of adverse events, changes in vital signs, laboratory and other safety parameters", 
            "measure": "Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "13  weeks"
        }, 
        "overall_contact": {
            "email": "info@lumenapharma.com", 
            "last_name": "Sara Barbat, BSN, RN", 
            "phone": "858-461-0694"
        }, 
        "overall_official": {
            "affiliation": "Lumena Pharmaceuticals, Inc.", 
            "last_name": "Alejandro Dorenbaum, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change from baseline in fasting serum bile acids compared to placebo", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "13 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01903460"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Change from baseline in liver enzymes and pruritus compared to placebo", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "13 weeks"
        }, 
        "source": "Lumena Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lumena Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}